BioCentury
ARTICLE | Company News

Lilly buys Siga's Priority Review voucher gained via smallpox approval

November 1, 2018 1:46 PM UTC

Eli Lilly and Co. (NYSE:LLY) acquired a Priority Review voucher from Siga Technologies Inc. (NASDAQ:SIGA) for $80 million. The voucher, which Siga obtained in July upon approval of TPOXX tecovirimat to treat smallpox, was the first FDA awarded under its Material Threat Medical Countermeasure voucher program.

TPOXX, an oral small molecule antiviral, is the first drug FDA has approved to treat smallpox (see "Siga Gets Priority Review Voucher For First Approved Smallpox Drug")...